Réglementation et droit · 11/12/19951 min de lecture
National Institute of Allergy and Infectious Diseases: Licensing Opportunity and/or Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Development of Influenza A PB2 Gene Technology
Traduction automatique locale · Langue originale de la source
Résumé
The National Institutes of Health is seeking licensees and/or CRADA Collaborators for the joint research, development, evaluation, and commercialization of its influenza A polymerase basic 2 (PB2) patent portfolio. The inventions claimed in U.S. Patent Application Serial No. 08/123,933 (``Method for Generating Influenza A Viruses Bearing Attenuating Mutations in Internal Protein Genes,'' filed September 20, 1993), and its related patent applications, are available for either co-exclusive or non-exclusive licensing (in accordance with 35 U.S.C. 207 and 37 CFR Part 404) and/or further development under one or more CRADAs for important clinical and research applications described below in the Supplementary Information section.